脑安胶囊在缺血性卒中二级预防中的作用  

Effects of Naoan Capsule(脑安胶囊) in Secondary Prevention Trial for Ischemic Stroke

作　　者：陈伟康[1] 蓝丽康[1] 卢丽萍[1] 邵蓓[2] 

机构地区：[1]温州医科大学附属第六医院,浙江丽水323000 [2]温州医科大学附属第一医院,浙江温州325000

出　　处：《中国中医药科技》2016年第2期136-138,共3页Chinese Journal of Traditional Medical Science and Technology

基　　金：浙江省丽水市科技计划项目

摘　　要：目的:评价脑安胶囊在急性缺血性卒中二级预防中的作用。方法:入选240例急性脑梗死患者,随机分成2组,对照组(拜阿司匹林100 mg+阿托伐他汀钙片20 mg)120例,脑安组(拜阿司匹林100mg+阿托伐他汀钙片20 mg+脑安胶囊4粒)120例,平均治疗并随访1年。于治疗前后检测2组患者血黏度及血脂水平,观察2组患者脑血管意外事件的发生率。完成随访226例,其中对照组114例,脑安组112例。结果:1)对照组脑血管意外事件累积发病17例(14.91%),其中脑梗死7例(6.14%),短暂性脑缺血发作(TIA)9例(7.9%),脑出血1例(0.88%),总死亡6例(5.2%);脑安组脑血管意外事件8例(7.14%),脑梗死3例(2.68%),TIA3例(2.68%),脑出血2例(1.79%),总死亡6例(5.4%)。两组比较,发生脑血管意外事件的累积发病率、脑梗死、TIA、脑出血、总死亡率均无统计学意义(P>0.05);而缺血性脑血管事件,包括脑梗死及TIA,两组资料比较,差异有统计学意义(P<0.05)。2)治疗后脑安组的NIHSS评分与对照组比较,差异有统计学意义(P<0.05)。3)治疗1年后2组患者全血黏度低切、血浆黏度(P<0.05)、纤维蛋白原(P<0.05)、总胆固醇(TC)及三酰甘油(TG)与治疗前比较均显著降低(P<0.05),且脑安组治疗后上述指标显著低于对照组,差异具有统计学意义(P<0.05)。结论:脑梗死患者在常规治疗的基础上加用脑安胶囊可以降低脑缺血性事件的发生率,不增加脑出血和死亡的风险,改善神经功能缺损症状,可以用于脑梗死患者的二级预防。Objective： To evaluate the effects of Naoan Capsule in the secondary prevention trial of ischemic stroke. Methods： 240 patients of ischemic stroke were randomly divided into control group and Naoan group, Each group contained 120 cases ,the control group was treated with aspirin 100 mg and atorvastatin 20 mg, the Naoan group was given Naoan Capsule （ two capsules twice everyday） on the basis of control group. The blood theology and blood lipid were determined before and after treatment, the incidence of cerebrovascular events was recorded. An average follow - up of 1 year. Finally 226 cases completed test, including the control group 114 eases, 112 cases of Naoan group. Results： 1 ）The control group with the cumulative incidence of 17 cases （ 14. 91% ） ,cerebral infarction 7 cases（6. 14% ） , transient ischemic attack （TIA） 9 cases（7. 9% ） , cerebral hemorrhage 1 case（0. 88% ）, death 6 cases（5.2% ） ;the Naoan group was respectively 8 cases（7. 14% ） ,3 cases（2. 68% ） ,3 cases（2. 68% ） ,2 cases（ 1.79% ） ,6 cases（5.4% ）. Compared the two groups, the cumulative incidence of eerebrovaseular events, TIA, cerebral hemorrhage, cerebral infarction, total mortality had no statistical significance （ P 〉 0. 05 ）. Comparison of the isehemic cerebrovascular events between the two groups, including cerebral infarction and TIA, showed significant difference （ P 〈 0. 05 ）. 2 ） The NIHSS score of Naoan group was improved obviously, compared with control group, the difference was statistically significant （P 〈 0.05 ）. 3 ） 1 years after treatment, the low blood viscosity （ P 〈 0. 05 ）, plasma viscosity （ P 〈 0. 05 ）, fibrinogen （ P 〈 0. 05 ）, total cholesterol（ P 〈 0. 05 ） and triglyeeride （ P 〈 0. 05 ） were significantly lowered after treatment （ P 〈 0. 05 ）, and the above indexes in Naoan group were significantly lower than those in the control group after treat-ment （ P 〈 0. 05 ）. Conclusion： Naoan capsule may

关 键 词：缺血性卒中 脑安胶囊 二级预防 人类 

分 类 号：R743.3[医药卫生—神经病学与精神病学]